Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03370120 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
406
Enrollment
INDUSTRY
Sponsor class

Stopped Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure

Conditions

Interventions

Sponsor

UCB Biopharma SRL